Fig. 3

LTH-sEV activates LX2 by transferring LIMA1 to LX2. A Western blot of LIMA1 in L02-shCtr and L02-shLIMA1. B Western blot of LIMA1 in LTH-sEVshCtr and LTH-sEVshLIMA1. C Western blot of sEV markers CD9, CD63, TSG101 and endoplasmic reticulum marker Calnexin in LTH-sEVshCtr and LTH-sEVshLIMA1. D Internalization of LTH-sEVshCtr and LTH-sEVshLIMA1 labeled with PKH26 into LX2. Scale bar = 50 μm. E Western blot of COL1A1, COL3A1, α-SMA and LIMA1 in LX2 treated with LTH-sEVshCtr or LTH-sEVshLIMA1. F–H qRT-PCR of COL1A1, COL3A1 and α-SMA mRNA in LX2 treated with LTH-sEVshCtr or LTH-sEVshLIMA1. I Immunofluorescence staining of α-SMA (red) in LX2 after accepting LTH-sEVshCtr or LTH-sEVshLIMA1. Scale bar = 20 μm. J Cell proliferation of LX2 treated with LTH-sEVshCtr or LTH-sEVshLIMA1 were determined by CCK-8 assays. All data were expressed as the means ± SD of at least 3 independent experiments, * P < 0.05; **P < 0.01; ***P < 0.001